Dmytro Kharkov

Bristol-Myers Squibb shares drop more than 3% after bearish technicals and ongoing workforce reductions

Bristol-Myers Squibb shares drop more than 3% after bearish technicals and ongoing workforce reductions
Bristol-myers squibb slides 3.33% today

Bristol-Myers Squibb Company (BMY) dropped 3.33% today after multiple institutional investors reduced their holdings, and ongoing cost-cutting actions remained in focus. The decline is supported by bearish near-term technicals, with BMY trading below its 20-day and 50-day moving averages.

BMY price prediction
24H 0.05%
$58.83
48H -0.29%
$58.63
7D -0.78%
$58.34
1M 5.66%
$62.13
3M 22.74%
$72.17
6M 41.72%
$83.33
12M 41.11%
$82.97
Current price: $58.8 0.4600 0.79%
Closed 11/20
Daily range 58.69 Arrow from to Icon 59.81
Weekly range 57.88 Arrow from to Icon 64.94
Loading...

Highlights

  • Institutional investors trimmed positions in Bristol-Myers Squibb during the third quarter and the company terminated a Cellares CAR-T partnership.
  • Bristol-Myers Squibb confirmed a quarterly dividend of $0.63 per share, maintaining a 4% yield with a 55.88% payout ratio as revenue rose 6.9% year-over-year.
  • Shares of Bristol-Myers Squibb trade below short-term averages under sustained downside pressure, with an expected five-day range of $59.05 to $62.64 and over 80% probability of consolidation or move higher.

Investor exits counter rising revenue amid persistent selling pressure

During the third quarter, several institutional investors reduced their positions in Bristol-Myers Squibb, including Machina Capital S.A.S., Patrick Mauro Investment Advisor INC., and Cullen Capital Management LLC, while White Pine Capital LLC started a new position. The company confirmed a quarterly dividend of $0.63 per share, maintaining a 4% yield and a payout ratio of about 55.88%. Revenue rose 6.9% year-over-year, with analysts expecting full-year EPS near 6.46. Workforce reductions and the termination of the Cellares CAR-T cell therapy partnership have also been disclosed, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, sees Bristol-Myers Squibb under clear pressure as institutional investors reduce stakes and the stock holds below crucial short-term averages. He highlights the company's fundamental challenges — workforce cuts, partnership terminations, and persistent selling — as signs of a shaky outlook. Technical signals remain mixed, yet the breach below the 20- and 50-day moving averages weighs on sentiment. Dividend stability and a healthy yield offer limited consolation amid these headwinds. "Until the stock recovers above $61.35 with strong volume, I view downside risks as dominant," Kharitonov states.
Viktoras Karapetjanc, expert at Traders Union, emphasizes the resilient aspects of Bristol-Myers Squibb’s setup. He sees robust fundamentals in the 6.9% revenue growth, sustained dividend yield, and consistent EPS outlook. Despite recent volatility and investor repositioning, Karapetjanc notes that longer-term support above $60.38 signals ongoing strength. He views the range-bound pattern as an opportunity for patient investors. "Bullish structure remains intact with further upside expected once $61.35 is cleared," Karapetjanc affirms.
Sholanke Dele, market strategist, points out the risk-averse sentiment driving Bristol-Myers Squibb’s decline. He says investor confidence has weakened as cost cuts, strategic exits, and technical breakdowns dominate the outlook. Macro factors and waning institutional participation add to downside pressure. "Market appetite is low, so any rally towards $61.35 is likely to face resistance," says Dele.
Bristol-Myers Squibb Company asset chart
Bristol-Myers Squibb Company price dynamics. Source: TradingView.

Short-term bearish trend persists as mixed technical signals emerge

Bristol-Myers Squibb is trading below its 20-day and 50-day moving averages ($62.30 and $61.83), but remains above the 200-day moving average ($60.38), indicating near-term bearish pressure with longer-term support holding. The Ichimoku Kijun at $60.85 acts as immediate support, with the next key floor at $60.73 and resistance at $61.35. Momentum indicators are mixed; MACD and Awesome Oscillator signal a bullish bias, ADX reads as neutral. Both the RSI and Stochastic RSI are neutral, while the CCI is in the overbought zone, suggesting caution for a potential downside correction. Bull/Bear Power is positive, indicating intraday buying momentum, even though the stock experienced a sharp pullback with price near session lows and volatility at 2.22%. This position reflects continued downside pressure despite some underlying bullish momentum signals.

Earlier, analysts noted that Bristol Myers Squibb raised its full-year revenue forecast amid strong demand for newer medicines, even as it faced acquisition-related charges and continued to see shifts in its product mix. The current technical setup, combined with the impact of institutional repositioning and cost-cutting measures, adds a layer of caution, making the $60.73 support and $61.35 resistance key levels to watch for a potential directional move in the coming sessions.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.